Pancreatic cancer is one of the most insidious forms of cancer. Recent estimates of new cancer cases put pancreatic cancer at eighth and ninth among women and men, respectively. However, it is the fourth leading cause of all cancer deaths in both women and men, surpassed only by lung, colorectal, prostate, and breast cancers. Due largely to the location, and silent growth of the tumor, most patients present at a time when it is too late to undergo any realistic type of curative treatment. This has translated into a 5-year survival rate of less than 3%. In a recent report, """"""""Pancreatic Cancer: An Agenda for Action"""""""", the NCI's Pancreatic cancer Progress Review Group drew specific attention to the urgent need for """"""""better screening and diagnostic techniques"""""""" with a recommendation to """"""""delineate and validate effective molecular biomarkers"""""""" for pancreatic cancer. With this in mind, we intend to develop and assess the utility of a PAM4, anti-MUC1 antibody-based immunoassay to detect, diagnose, and provide for the management of this disease. Although there have been several reports concerning anti-MUC1 MAbs reactive with several types of cancer, PAM4 appears to be unique, or nearly so, in terms of its specificity and the molecular characteristics of the epitope to which it is reactive. The long-term objective of this proposal is to identify specific biomarkers that can be combined with the PAM4 assay for enhanced diagnostic accuracy of pancreatic cancer.
The specific aims of this proposal are Aim 1. To investigate the diagnostic accuracy of an immunoassay for the quantitation of PAM4-reactive MUC1 in biological fluids as a means for early detection and diagnosis of pancreatic cancer.
Aim 2. To investigate the heterogeneity in expression of MUC1 epitope structures as a means to identify patterns that may be organ and/or tumor """"""""specific/associated"""""""".
Aim 3. To investigate whether inclusion of other mucin biomarkers can increase diagnostic accuracy through multivariate analyses.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA096924-04
Application #
7459750
Study Section
Special Emphasis Panel (ZRG1-CBSS (01))
Program Officer
Thurin, Magdalena
Project Start
2005-09-09
Project End
2009-06-30
Budget Start
2008-07-01
Budget End
2009-06-30
Support Year
4
Fiscal Year
2008
Total Cost
$241,362
Indirect Cost
Name
Center for Molecular Medicine/Immunology
Department
Type
DUNS #
118870583
City
Morris Plains
State
NJ
Country
United States
Zip Code
07950
Liu, Donglin; Chang, Chien-Hsing; Gold, David V et al. (2015) Identification of PAM4 (clivatuzumab)-reactive epitope on MUC5AC: a promising biomarker and therapeutic target for pancreatic cancer. Oncotarget 6:4274-85
Shi, Chanjuan; Merchant, Nipun; Newsome, Guy et al. (2014) Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry. Arch Pathol Lab Med 138:220-8
Gold, David V; Gaedcke, Jochen; Ghadimi, B Michael et al. (2013) PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma. Cancer 119:522-8
Sopha, Sabrina C; Gopal, Purva; Merchant, Nipun B et al. (2013) Diagnostic and therapeutic implications of a novel immunohistochemical panel detecting duodenal mucosal invasion by pancreatic ductal adenocarcinoma. Int J Clin Exp Pathol 6:2476-86
Gold, David V; Newsome, Guy; Liu, Donglin et al. (2013) Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin. Mol Cancer 12:143
Ocean, Allyson J; Pennington, Kenneth L; Guarino, Michael J et al. (2012) Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial. Cancer 118:5497-506
Gulec, Seza A; Cohen, Steven J; Pennington, Kenneth L et al. (2011) Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I single-dose escalation trial. Clin Cancer Res 17:4091-100
Gold, David V; Stein, Rhona; Burton, Jack et al. (2010) Enhanced expression of CD74 in gastrointestinal cancers and benign tissues. Int J Clin Exp Pathol 4:1-12
Gold, David V; Goggins, Michael; Modrak, David E et al. (2010) Detection of early-stage pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 19:2786-94
Modrak, David E; Leon, Evelyn; Goldenberg, David M et al. (2009) Ceramide regulates gemcitabine-induced senescence and apoptosis in human pancreatic cancer cell lines. Mol Cancer Res 7:890-6

Showing the most recent 10 out of 12 publications